Mutation profile in non-small cell lung cancer: Analysis of a Brazilian population.

Lung cancer in Brazil

“…Some efforts have been made to compile data on the frequency of molecular abnormalities in Brazilian patients ( Table 2 ). 40 - 48 Overall, the data suggest that the frequency of EGFR mutations is lower in Brazil (approximately 25%) than in Asia but higher than in White populations in North America and Europe ( Figure 3 ), confirming findings from other Latin American countries. 49 It has been speculated that the ethnic background could be responsible for the distinct molecular profile seen in these instances, perhaps due to the characteristic genetic admixture seen in Brazilians, inherited from European, African, and Native American ancestors.…”

“…The frequency of ALK translocations has been reported to range from 3% to 4%. 48 , 50 , 51 To explore these points in a better way, two multicenter studies have been initiated, led by the Brazilian National Clinical Cancer Research Network and the Latin American Cooperative Oncology Group. These consortiums are supported by pharmaceutical companies, as well as by North American societies, such as the American Society of Clinical Oncology and the American Association for Cancer Research.…”

The importance of molecular characterization in lung cancer

“…Using immunohistochemistry with the D5F3 clone, they detected ALK expression in 10.4% of the samples, and immunohistochemistry with the SP263 clone revealed a surprisingly low (50.9%) rate of PD-L1 positivity. In comparison with other studies conducted in Brazil, the EGFR mutation rate was similar, 8 whereas the level of ALK expression was higher 9 . Selection bias (due to geographic limitations and small sample sizes) could explain those discrepancies.…”

Análise de custo-efetividade do painel de sequenciamento de nova geração do DNA circulante tumoral no diagnóstico dos pacientes com câncer de pulmão de não pequenas células não escamoso metastático

“…A prevalência das alterações nos genes EGFR e ALK em pacientes com CPNPC foi retirada de estudos brasileiros, sendo 25,5% e 4%, respectivamente (Pontes et al, 2014;Gomes et al, 2015).…”